Testing intravitreal toxicity of rapamycin in rabbit eyes;Toxicidade intravítrea da rapamicina em olhos de coelhos

Arquivos Brasileiros de Oftalmologia

Volumn 72, Issue 1, 2009, Pages 18-22

  de Almeida Manzano, Roberta Pereira ^a,b   Peyman, Gholam A ^c   Khan, Palwasha ^d   Kivilcim, Muhamet ^c,d   Chevez Barrios, Patricia ^e   Takahashi, Walter ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Santa Casa de Misericórdia de São Paulo ^*  (Brazil)

^c UNIVERSITY OF ARIZONA   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Choroidal neovascularization; Rabbits; Sirolimus toxicity; Uveitis; Vascular endothelial growth factor receptor 1

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANIMAL; ANIMAL MODEL; ARTICLE; DRUG EFFECT; PATHOLOGY; RABBIT; RETINA; VITREOUS BODY;

ANIMALS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ANIMAL; RABBITS; RETINA; SIROLIMUS; VITREOUS BODY;

EID: 68249093493     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492009000100004     Document Type: Article

References (36)

1. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28(10):727-32.
2. Dupont P, Warrens AN. The evolving role of sirolimus in renal transplantation. QJM. 2003;96(6):401-9.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14):1315-23.
4. Comment in: N Engl J Med. 2003;349(14):1307-9.
5. N Engl J Med. 2004;350(4):413-4; author reply 413-4.
6. N Engl J Med. 2004;350(4): 413-4; author reply 413-4.
7. Gregory CR, Huie P, Billingham ME, Morris LE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 1993;55(6):1409-18.
8. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335-40.
9. Republished in: Clin Biochem. 2006;39(5):484-9.
10. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335-48.
11. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 2005;65(12):5325-36.
12. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8(2):128-35.
13. Comment in: Kidney Int. 2003;63(3):1160-1.
14. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol. 1994;112(11):1471-5.
15. Erratum in: Arch Ophthalmol 1995; 113(2):144.
16. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis. 2004;10:964-72.
17. Ikeda E, Hikita N, Eto K, Moshisuki M. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn J Ophthalmol. 1997; 41(6):396-402.
18. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol. 1995;154(2):922-7.
19. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM, Dua HS. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89(6):666-9.
20. Mizota A, Adachi-Usami E. Effect of body temperature on electroretinogram of mice. Invest Ophthalmol Vis Sci. 2002;43(12):3754-7.
21. Lachapelle P, Benoit J, Guité P. The effect of in vivo retinal cooling on the electroretinogram of the rabbit. Vision Res. 1996;36(3):339-44.
22. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795-803.
23. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246(4935):1306-9.
24. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37(9):1929-34.
25. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.
26. Comment in: ACP J Club. 2005;143(1):18.
27. N Engl J Med. 2004;351(27):2863-5.
28. N Engl J Med. 2005;352(16):1720-1; author reply 1720-1.
29. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Opthalmology. 2006;113(6): 992-1001.e6.
30. Michels S, Rosenfeld PJ. Ranibizumab therapy for neovascular age related macular degeneration. Retinal Physician. 2004;1(1):16-22.
31. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623.e1.
32. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-72.e5.
33. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22(20):7004-14.
34. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997;272(38): 23659-67.
35. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002;16(8):771-80. Erratum in: FASEB J. 2006;20(9):1573.
36. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277(31):27975-81.